We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Vivek Venkatramani MD

Vivek Venkatramani MD

Consultant Uro-Oncologist, Nanavati Super-Speciality Hospital, Mumbai, India; Visiting Assistant Professor, Department of Urology, University of Miami Miller School of Medicine, Miami, Florida

Dr. Vivek Venkatramani is a Consultant Uro-oncologist and robotic urologist in Mumbai, India. He completed his fellowship in Urologic Oncology and Robotic Urology at the University of Miami Miller School of Medicine. He served as faculty for 1-year after his fellowship and is presently a Visiting Assistant Professor to the University of Miami. 

He was an integral contributor to the landmark randomized open versus robotic cystectomy (RAZOR) trial, the world’s first phase 3 multicenter randomized trial comparing open to robotic surgery in any organ site, which was published in the prestigious journal The Lancet in June 2018. 

He is a gold-medalist urologist from the noted Christian Medical College, Vellore, and completed his M.S. General Surgery from KEM Hospital, Mumbai. He won the “CKP Menon Best Paper Ward” at Urological Society of India conference in 2013 and the “Seetharaman Best Essay Award” in 2014. He has numerous publications  to his credit and has co-authored book chapters in Uro-oncology.